HK data: Durvalumab consolidation post-CRT improves PFS in stage III unresectable NSCLC
29 Jan 2026
byDr. Sheona Leung, Associate Consultant, Department of Oncology, Princess Margaret Hospital; Dr. Fiona Lim, Consultant, Department of Oncology, Princess Margaret Hospital; Dr. Tracy Lau, Associate Consultant, Department of Oncology, Princess Margaret Hospital
Durvalumab consolidation therapy following concurrent chemoradiotherapy (CRT) extends median progression-free survival (mPFS) in Hong Kong patients with unresectable stage III non-small-cell lung cancer (NSCLC), and also demonstrates a manageable safety profile, according to a real-world study at the Department of Oncology, Princess Margaret Hospital (PMH) conducted by Associate Consultant Dr Sheona Leung, Consultant Dr Fiona Lim, and Associate Consultant Dr Tracy Lau.